Although the authors did not investigate in detail the mechanism of the anti-leukemia activity of pyrvinium in the MLL samples, they showed lack of β-catenin protein in MLL-rearranged AML cells and, at the same time, mitochondrial localization of the drug in the MLL cells. This evidence concerns the gene KMT2A and acute myeloid leukemia.